Business Description
10x Genomics Inc
NAICS : 621999
SIC : 8099
ISIN : US88025U1097
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.08 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.47 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.09 | |||||
Beneish M-Score | -3.59 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.4 | |||||
3-Year EBITDA Growth Rate | 29.9 | |||||
3-Year EPS without NRI Growth Rate | 25.9 | |||||
3-Year FCF Growth Rate | 39.8 | |||||
3-Year Book Growth Rate | -3 | |||||
Future 3-5Y Total Revenue Growth Rate | 13.83 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 17.7 | |||||
9-Day RSI | 21.1 | |||||
14-Day RSI | 23.77 | |||||
6-1 Month Momentum % | -5.44 | |||||
12-1 Month Momentum % | -28.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 4.11 | |||||
Cash Ratio | 3.06 | |||||
Days Inventory | 140.22 | |||||
Days Sales Outstanding | 57.64 | |||||
Days Payable | 37.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 66.15 | |||||
Operating Margin % | -42.88 | |||||
Net Margin % | -41.23 | |||||
FCF Margin % | -10.56 | |||||
ROE % | -32.81 | |||||
ROA % | -25.79 | |||||
ROIC % | -51.86 | |||||
ROC (Joel Greenblatt) % | -55.27 | |||||
ROCE % | -28.44 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.1 | |||||
PB Ratio | 4.32 | |||||
Price-to-Tangible-Book | 4.45 | |||||
EV-to-EBIT | -11.71 | |||||
EV-to-Forward-EBIT | -13.95 | |||||
EV-to-EBITDA | -14.2 | |||||
EV-to-Forward-EBITDA | -16.75 | |||||
EV-to-Revenue | 4.71 | |||||
EV-to-Forward-Revenue | 4.29 | |||||
EV-to-FCF | -45 | |||||
Price-to-Net-Current-Asset-Value | 8.62 | |||||
Price-to-Net-Cash | 19.49 | |||||
Earnings Yield (Greenblatt) % | -8.54 | |||||
FCF Yield % | -2.02 |